The MITRIS RESILIA valve is built on the trusted Carpentier-Edwards PERIMOUNT platform, which in 2021, celebrates 40 years of innovative valve replacements for patients. About Edwards Lifesciences ...

The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral position. The Mitris Resilia valve has a ...

The MITRIS RESILIA valve resembles the asymmetric shape of the native mitral valve. It has a low-profile frame that helps prevent stent posts from obstructing the left ventricular outflow tract.

The intervention being tested is the MITRIS RESILIA Mitral Valve, a device designed for the surgical replacement of native or prosthetic mitral valves. Its purpose is to enhance the safety and ...

The RESILIA tissue data from the trial reported encouraging results through eight years, with low rates of structural valve deterioration (99.3% freedom from SVD in the RESILIA tissue group versus ...